Torrent Pharma Launches Oral and Injectable Semaglutide in India
Torrent Pharmaceuticals has announced the launch of both oral and injectable formulations of semaglutide in India, marking a significant milestone in the country’s diabetes and weight management treatment landscape. The company has become the first in India to introduce a generic version of oral semaglutide, expanding access to an advanced therapy that was previously limited due to high costs.
In addition to the oral variant, Torrent Pharma has also launched the injectable form of semaglutide at a starting price of ₹3,999 per month, making it a more affordable option for patients. Semaglutide, a GLP-1 receptor agonist, is widely recognized for its effectiveness in controlling blood sugar levels and aiding weight loss, making it a preferred treatment for type 2 diabetes and obesity.
The launch is expected to intensify competition in the segment and improve accessibility of innovative therapies in India. With a growing burden of diabetes in the country, Torrent Pharma’s move aligns with the increasing demand for effective and cost-efficient treatment options.